Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Global equity funds attracted significant inflows in the week ending February 12, after a Bank of England rate cut drove a ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered ...

A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...

Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...